Table 4

Additional univariate meta-regression results

OutcomeYear of publicationCohort, numberAverage age at diagnosis (years)Cohort, numberAge at entry (years)Cohort, numberDisease duration at entry (months)Cohort, number
SDI difference0.96
(0.92 to 1.00)
(0.037, 10.2%)
291.01
(0.99 to 1.04)
(0.3351, 0%)
271.01 (0.99 to 1.04)
(0.404, 0%)
281.00 (0.99 to 1.01)
(0.972, 0%)
27
Cataracts0.95
(0.88 to 1.02)
(0.162, 2.3%)
171.05
(1.00 to 1.09)
(0.028, 22.0%)
161.04
(1.01 to 1.08)
(0.023, 19.3%)
171.01
(0.99 to 1.02)
(0.372, 0%)
16
CVA0.96
(0.92 to 1.00)
(0.052, 22.6%)
151.02
(0.95 to 1.09)
(0.555, 0%)
131.00
(0.95 to 1.05)
(0.941, 0%)
151.00
(0.99 to 1.01)
(0.356,0%)
13
MI0.95
(0.91 to 0.99)
(0.018, 37.4%)
161.08
(1.04 to 1.13)
(<0.001, 71.8%)
141.06
(1.00 to 1.12)
(0.035, 30.3%)
150.99
(0.98, 1.00)
(0.175, 18.6%)
14
Overall
CVE
0.99
(0.95 to 1.05)
(0.831, 0%)
181.06
(1.01 to 1.13)
(0.031, 36.4%)
151.08
(1.04 to 1.12)
(<0.001, 61.7%)
171.01
(0.99 to 1.03)
(0.081, 14.7%)
15
Osteonecrosis1.00
(0.96 to 1.04)
(0.93, 1.0%)
220.93
(0.86 to 1.00)
(0.063, 9.7%)
210.97
(0.89 to 1.05)
(0.41, 4,0%)
221.01
(1.00 to 1.02)
(0.115, 3.1%)
21
Osteoporosis and fractures1.00
(0.90 to 1.11)
(0.97, 1.0%)
161.05
(0.99 to 1.12)
(0.112, 14.0%)
161.06
(1.01 to 1.12)
(0.016, 36.0%)
161.02
(1.01 to 1.03)
(0.003, 49.9%)
16
  • Relative risks, CI (,) and p values plus R2 values (…) for variables with information from three or more studies. Potentially significant effects are bolded for a positive relationship (higher value, more damage) and in italics for a negative relationship (lower value, more damage).